
Product Data Sheet

Product Name: Metiamide

Cat. No.: GC13024

Chemical Properties

Cas. No. 34839-70-8

Chemical Name 1-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]thiourea

SMILES CC1=C(N=CN1)CSCCNC(=S)NCFormula $C_9H_{16}N_4S_2$ M.Wt 244.38Solubility DMSO : 2.4 mg/mL (9.82 mM; Need ultrasonic and warming); H₂O : 1.67 mg/mL (6.83 mM; ultrasonic and warming and heat to 60°C) Store Storage at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Background**

Metiamide is a high-selective and oral bioavailable antagonist of histamine H₂-receptor with ED₅₀ value of 25 μmol/kg [1].

Unlike the traditional antihistaminics which are H₁-receptor antagonists, metiamide is an antagonist of H₂-receptor. It is developed from burimamide which is a previously found antagonist of H₂-receptor. Metiamide acts as a competitive antagonist and blocks the combination of histamine and its receptor. This blockade results in the inhibition of gastric acid secretion stimulated by histamine and other hormone such as pentagastrin and gastrin. Compared with burimamide, metiamide showed higher activity and good oral bioavailability [1 and 2].

In the in vitro assays, metiamide displayed about 10-fold higher activity than burimamide on rat uterine muscle and guinea-pig heart muscle with K_b values of 0.75 and 0.92 μM, respectively. The K_b value of burimamide on the atrial muscle was 7.8 μM.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Besides that, metiamide showed no efficacy on H1-receptor and isoprenaline even at the concentration of 1 mM suggested that metiamide was also a selective antagonist. Moreover, metiamide was found to cause increase in chemokinesis and random migration in PMN cells similar to histamine. It was different that metiamide had no effects on the true chemotaxis whereas histamine significantly suppressed the chemotaxis, which demonstrated histamine affected neutrophil motility through the H2-receptor site [1 and 3].

In dogs, the administration of metiamide inhibited acid secretion stimulated by histamine from both the Heidenhain pouch and the gastric fistula. It also inhibited acid secretion stimulated by pentagastrin and liver extract from both the Heidenhain pouch and the main stomach. When metiamide was given by intravenous injection, the doses of it to cause 50% inhibition of the maximal histamine- and pentagastrin-stimulated acid secretion were 3.1 and 6.1 $\mu\text{mol/kg}$. When metiamide was given by oral administration, the ED50 value of it to cause inhibition was 16 $\mu\text{mol/kg}$ [1 and 2].

References:

- [1] Black J W, Duncan W A M, Emmett J C, et al. Metiamide—an orally active histamine H2-receptor antagonist. *Agents and Actions*, 1973, 3(3): 133-137.
- [2] Grossman M I, Konturek S J. Inhibition of acid secretion in dog by metiamide, a histamine antagonist acting on H2 receptors. *Gastroenterology*, 1974, 66(4): 517-521.
- [3] Anderson R, Glover A, Rabson A R. The *in vitro* effects of histamine and metiamide on neutrophil motility and their relationship to intracellular cyclic nucleotide levels. *The Journal of Immunology*, 1977, 118(5): 1690-1696.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA
